Skip to main content
Signal8

Coleman Jamie Beth

SEC insider (Form 3/4/5 filer). CIK 0002118765. Chief Commercial Officer at Kailera Therapeutics, Inc. (KLRA). 2 reported Form 4/5 transactions since Sep 2024; latest on Apr 16, 2026. Located in WALTHAM, MA.

Companies Coleman Jamie Beth has filed insider reports for

  • Kailera Therapeutics, Inc. (KLRA): Officer, Chief Commercial Officer
Coleman Jamie Beth profile photo

Coleman Jamie Beth

CIK: 0002118765

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Kailera Therapeutics, Inc. logo
KLRA

Kailera Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

  • Kailera Therapeutics, Inc. logo
    KLRA

    Kailera Therapeutics, Inc.

    Apr 16, 2026
    Award

    Stock Option (right to buy)

    Direct
    75K shares-
  • Kailera Therapeutics, Inc. logo
    KLRA

    Kailera Therapeutics, Inc.

    Apr 16, 2026
    Award

    Stock Option (right to buy)

    Direct
    75K shares-

1-2 of 2